FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980649413> ?p ?o ?g. }

• W2980649413 endingPage "76" @default.
• W2980649413 startingPage "65" @default.
• W2980649413 abstract "Abstract Studies of anticancer therapies in traditional cell culture models can demonstrate efficacy of direct-acting compounds but lack the 3-dimensional arrangement of the tumor cells and their tissue-specific microenvironments, both of which are important modulators of treatment effects in vivo. Bone cells reside in complex environments that regulate their fate and function. A bioengineered human bone-tumor model has been shown to provide a microphysiological niche for studies of cancer cell behavior. Here, we demonstrate successful transfer between 2 laboratories and utility of this model in efficacy studies using well-established chemotherapeutic agents. The bioengineered human bone-tumor model consisted of Ewing sarcoma (RD-ES) cancer cell aggregates infused into tissue-engineered bone that was grown from human mesenchymal stem cell-derived differentiated into osteoblasts within mineralized bone scaffolds. The tumor model was maintained in culture for over 5 weeks and subjected to clinically relevant doses of linsitinib, doxorubicin, cisplatin, methotrexate, vincristine, dexamethasone, or MAP (methotrexate, doxorubicin, and cisplatin combination). Drug administration cycles were designed to mimic clinical treatment regimens. The bioengineered tumors were evaluated days to weeks after the cessation of treatment to monitor the potential for relapse, using bioengineered bone and ES cell monolayers as controls. Drug binding to the scaffolds and media proteins and gene expression were also evaluated. We show that a bioengineered human bone tumor can be used as a microphysiological model for preclinical studies of anticancer drugs. We found that anticancer efficacy was achieved at concentrations approximating the human Cmax, in contrast to traditional ES cell monolayers. These studies show that the bone-tumor model can be successfully transferred between laboratories and has predictive power in preclinical studies. The effects of drugs on the bone tumors and healthy bone were studied in parallel, in support of the utility of this model for identification of new therapeutic targets." @default.
• W2980649413 created "2019-10-25" @default.
• W2980649413 creator A5018335177 @default.
• W2980649413 creator A5019868317 @default.
• W2980649413 creator A5027397488 @default.
• W2980649413 creator A5044516331 @default.
• W2980649413 creator A5063229011 @default.
• W2980649413 creator A5078414342 @default.
• W2980649413 creator A5084546123 @default.
• W2980649413 creator A5091590545 @default.
• W2980649413 date "2019-10-18" @default.
• W2980649413 modified "2023-10-18" @default.
• W2980649413 title "Tissue-Engineered Bone Tumor as a Reproducible Human <i>in Vitro</i> Model for Studies of Anticancer Drugs" @default.
• W2980649413 cites W1582086438 @default.
• W2980649413 cites W1593757293 @default.
• W2980649413 cites W1967302620 @default.
• W2980649413 cites W1991102099 @default.
• W2980649413 cites W2018977233 @default.
• W2980649413 cites W2043784829 @default.
• W2980649413 cites W2049426260 @default.
• W2980649413 cites W2056996061 @default.
• W2980649413 cites W2067786443 @default.
• W2980649413 cites W2091129297 @default.
• W2980649413 cites W2094049785 @default.
• W2980649413 cites W2124073148 @default.
• W2980649413 cites W2158217645 @default.
• W2980649413 cites W2164488758 @default.
• W2980649413 cites W2179438025 @default.
• W2980649413 cites W2301752180 @default.
• W2980649413 cites W2377678020 @default.
• W2980649413 cites W2408293494 @default.
• W2980649413 cites W2436232609 @default.
• W2980649413 cites W2507411843 @default.
• W2980649413 cites W2508222492 @default.
• W2980649413 cites W2516679939 @default.
• W2980649413 cites W2526193113 @default.
• W2980649413 cites W2529881898 @default.
• W2980649413 cites W2542819394 @default.
• W2980649413 cites W2569917156 @default.
• W2980649413 cites W2590614416 @default.
• W2980649413 cites W2602357293 @default.
• W2980649413 cites W2620093920 @default.
• W2980649413 cites W2626436465 @default.
• W2980649413 cites W2766283631 @default.
• W2980649413 cites W2792804408 @default.
• W2980649413 cites W2793367223 @default.
• W2980649413 cites W2802127533 @default.
• W2980649413 cites W2895351357 @default.
• W2980649413 cites W2912840511 @default.
• W2980649413 cites W2914058317 @default.
• W2980649413 cites W2938260053 @default.
• W2980649413 cites W38569268 @default.
• W2980649413 cites W4293767581 @default.
• W2980649413 doi "https://doi.org/10.1093/toxsci/kfz220" @default.
• W2980649413 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8204946" @default.
• W2980649413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31626302" @default.
• W2980649413 hasPublicationYear "2019" @default.
• W2980649413 type Work @default.
• W2980649413 sameAs 2980649413 @default.
• W2980649413 citedByCount "8" @default.
• W2980649413 countsByYear W29806494132020 @default.
• W2980649413 countsByYear W29806494132021 @default.
• W2980649413 countsByYear W29806494132022 @default.
• W2980649413 countsByYear W29806494132023 @default.
• W2980649413 crossrefType "journal-article" @default.
• W2980649413 hasAuthorship W2980649413A5018335177 @default.
• W2980649413 hasAuthorship W2980649413A5019868317 @default.
• W2980649413 hasAuthorship W2980649413A5027397488 @default.
• W2980649413 hasAuthorship W2980649413A5044516331 @default.
• W2980649413 hasAuthorship W2980649413A5063229011 @default.
• W2980649413 hasAuthorship W2980649413A5078414342 @default.
• W2980649413 hasAuthorship W2980649413A5084546123 @default.
• W2980649413 hasAuthorship W2980649413A5091590545 @default.
• W2980649413 hasBestOaLocation W29806494132 @default.
• W2980649413 hasConcept C126322002 @default.
• W2980649413 hasConcept C133605539 @default.
• W2980649413 hasConcept C142724271 @default.
• W2980649413 hasConcept C150903083 @default.
• W2980649413 hasConcept C185592680 @default.
• W2980649413 hasConcept C198826908 @default.
• W2980649413 hasConcept C207001950 @default.
• W2980649413 hasConcept C2776694085 @default.
• W2980649413 hasConcept C2776755627 @default.
• W2980649413 hasConcept C2777760704 @default.
• W2980649413 hasConcept C2778239845 @default.
• W2980649413 hasConcept C2779429289 @default.
• W2980649413 hasConcept C2781303535 @default.
• W2980649413 hasConcept C502942594 @default.
• W2980649413 hasConcept C54355233 @default.
• W2980649413 hasConcept C71924100 @default.
• W2980649413 hasConcept C81885089 @default.
• W2980649413 hasConcept C86803240 @default.
• W2980649413 hasConcept C98274493 @default.
• W2980649413 hasConceptScore W2980649413C126322002 @default.
• W2980649413 hasConceptScore W2980649413C133605539 @default.
• W2980649413 hasConceptScore W2980649413C142724271 @default.
• W2980649413 hasConceptScore W2980649413C150903083 @default.
• W2980649413 hasConceptScore W2980649413C185592680 @default.

• next